Crizotinib在ALK基因阳性非小细胞肺癌中的临床研究进展  

Clinical research progress of crizotinib in ALK-positive non-small cell lung cancer patients

作　　者：唐敏[1] 武晓楠[1] 程刚[1] 

机构地区：[1]卫生部北京医院肿瘤内科,北京100730

出　　处：《基础医学与临床》2013年第3期382-386,共5页Basic and Clinical Medicine

摘　　要：Crizotinib是小分子ATP竞争性抑制剂,对间变性淋巴瘤激酶(ALK)和肝细胞生长因子受体(c-Met/HGFR)以及它们的致癌变异体有选择性抑制作用。在临床研究PROFILE 1001和PROFILE 1005中,ALK重排阳性NSCLC患者对crizotinib有效率达50%～60%,大多数不良反应为1～2度。Vysis ALK breakapart FISH probe kit为检测ALK重排的标准方法。ALK重排更易出现在不吸烟或少吸烟的肺腺癌患者中。crizotinib的耐药机制比较复杂。Crizotinib is a selective ATP-competitive inhibitor of anaplastic lymphoma kinase （ ALK）, hepatocyte growth factor receptor（c-Met/HGFR） tyrosine kinases and their oncogenic variants. In PROFILE 1001 and PROFILE 1005 clinical trials, the response rate of crizotinib is 50% ~ 60% for non-small cell lung cancer（NSCLC） patients with ALK rearrangement. Most of the adverse events are grade 1 ~ 2. Vysis ALK breakapart a standard diagnostic test to detect ALK-rearrangement. ALK-rearrangement is more often seen in ers with lung adenocarcinomas. The mechanism of crizotinib resistance is complicated. FISH probe kit is never/light smok ers with lung adenocarcinomas. The mechanism of crizotinib resistance is complicated.

关 键 词：克唑替尼 间变性淋巴瘤激酶基因重排 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]